SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CUDC-907

Item No. 25651

CAS Registry No.: 1339928-25-4
Formal Name: N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl) thieno[3,2-d]pyrimidin-6-yl] methyl]methylamino]-5-pyrimidinecarboxamide
Synonym: Fimepinostat
MF: $C_{23}H_{24}N_8O_4S$
FW: 508.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CUDC-907 is supplied as a solid. A stock solution may be made by dissolving the CUDC-907 in the solvent of choice. CUDC-907 is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

CUDC-907 is a dual inhibitor of HDACs and phosphatidylinositol 3-kinases (PI3Ks).[1] It inhibits HDAC activity in HeLa nuclear extracts (IC_{50} = <0.1 µM) as well as the PI3K isoforms PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC_{50}s = <0.1, <1, <1, and <0.1 µM, respectively, for human recombinant enzymes). CUDC-907 inhibits cell growth in a panel of colon, pancreatic, non-small cell lung cancer (NSCLC), and multiple myeloma cells (IC_{50}s = <10-100 nM). It induces cell cycle arrest at the G_2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines in a concentration-dependent manner.[2] CUDC-907 (75 mg/kg) reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model.

References

1. Bao, R., Chengjung, L., and Changgeng, Q. Treatment of cancers having k-ras mutations. *Curis, Inc.* **WO2011130628A1** (2011).
2. Kotian, S., Zhang, L., Boufraqech, M., *et al.* Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. *Clin. Cancer Res.* **23(17)**, 5044-5054 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM